Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

True North Therapeutics
951 Gateway Blvd.
South San Francisco, CA 94080

True North Therapeutics is a biotechnology company developing a pipeline of novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in diseases with high unmet need, including rare diseases. The company's lead drug candidate, TNT009, offers a novel approach for treating Complement-mediated diseases by selectively inhibiting a target in the Classical Complement pathway. True North's antibody drug development is focused on the treatment of rare diseases mediated by the Complement system in the hematologic, kidney transplant, and skin therapeutic areas.

Key Contact
Name
Nancy Stagliano
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
04/07/15 $35,000,000 Series B Baxter Ventures
MPM Capital
OrbiMed Advisors
SR One
undisclosed
12/03/15 $40,000,000 Series C Baxalta Ventures
Cowen Private Investments
MPM Capital
New Leaf Venture Partners
OrbiMed Advisors
Perceptive Advisors
SR One
undisclosed
10/18/16 $45,000,000 Series D Franklin Templeton
HBM Healthcare Investments
Perceptive Advisors
Redmile Group
undisclosed


Featured Reading